272 related articles for article (PubMed ID: 23354011)
1. Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study.
Platzbecker U; Braulke F; Kündgen A; Götze K; Bug G; Schönefeldt C; Shirneshan K; Röllig C; Bornhäuser M; Naumann R; Neesen J; Giagounidis A; Hofmann WK; Ehninger G; Germing U; Haase D; Wermke M
Leukemia; 2013 Jun; 27(6):1403-7. PubMed ID: 23354011
[No Abstract] [Full Text] [Related]
2. Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?
Zeidan AM; Gore SD; Komrokji RS
Expert Rev Hematol; 2013 Jun; 6(3):251-4. PubMed ID: 23782079
[TBL] [Abstract][Full Text] [Related]
3. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G
Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423
[TBL] [Abstract][Full Text] [Related]
4. Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.
Möllgård L; Saft L; Treppendahl MB; Dybedal I; Nørgaard JM; Astermark J; Ejerblad E; Garelius H; Dufva IH; Jansson M; Jädersten M; Kjeldsen L; Linder O; Nilsson L; Vestergaard H; Porwit A; Grønbæk K; Hellström-Lindberg E
Haematologica; 2011 Jul; 96(7):963-71. PubMed ID: 21719884
[TBL] [Abstract][Full Text] [Related]
5. Azacitidine and lenalidomide as an alternative treatment for refractory acute myeloid leukemia: a case report.
Todaro J; Bollmann PW; Rother ET; del Giglio A
Sao Paulo Med J; 2015; 133(3):271-4. PubMed ID: 25250799
[TBL] [Abstract][Full Text] [Related]
6. "Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)".
Rasmussen B; Göhring G; Bernard E; Nilsson L; Tobiasson M; Jädersten M; Garelius H; Dybedal I; Grønbaek K; Ejerblad E; Lorenz F; Flogegård M; Marcher CW; Öster Fernström A; Cavelier L; Papaemmanuil E; Ebeling F; Kittang AO; Nørgaard JM; Saft L; Möllgård L; Hellström-Lindberg E
Leukemia; 2022 May; 36(5):1436-1439. PubMed ID: 35277655
[No Abstract] [Full Text] [Related]
7. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.
Stahl M; Zeidan AM
Cancer; 2017 May; 123(10):1703-1713. PubMed ID: 28192601
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.
Prebet T; Charbonnier A; Gelsi-Boyer V; Mozziconacci MJ; Blaise D; Vey N
Leuk Lymphoma; 2013 Jul; 54(7):1538-40. PubMed ID: 23110702
[No Abstract] [Full Text] [Related]
9. Lenalidomide for del(5q) and non-del(5q) myelodysplastic syndromes.
Giagounidis AA
Semin Hematol; 2012 Oct; 49(4):312-22. PubMed ID: 23079061
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities.
Chen Y; Kantarjian H; Estrov Z; Faderl S; Ravandi F; Rey K; Cortes J; Borthakur G
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):341-4. PubMed ID: 22579233
[TBL] [Abstract][Full Text] [Related]
11. Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide.
Sugimoto Y; Sekeres MA; Makishima H; Traina F; Visconte V; Jankowska A; Jerez A; Szpurka H; O'Keefe CL; Guinta K; Afable M; Tiu R; McGraw KL; List AF; Maciejewski J
J Hematol Oncol; 2012 Mar; 5():4. PubMed ID: 22390313
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency.
Arcioni F; Roncadori A; Di Battista V; Tura S; Covezzoli A; Cundari S; Mecucci C;
Eur J Haematol; 2018 Jul; 101(1):78-85. PubMed ID: 29569278
[TBL] [Abstract][Full Text] [Related]
13. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
[TBL] [Abstract][Full Text] [Related]
14. [5-day decitabine for treatment of myelodysplastic syndromes with complex karyotype abnormalities and acute myeloid leukemia].
Gao S; Hu XH; Qiu HY; Xu Y; Jin ZM; He GS; Tang XW; Han Y; Chen SN; Sun AN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2013 Jun; 34(6):542-3. PubMed ID: 23827117
[No Abstract] [Full Text] [Related]
15. Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide.
Gaballa MR; Besa EC
Ann Hematol; 2014 May; 93(5):723-33. PubMed ID: 24627193
[TBL] [Abstract][Full Text] [Related]
16. Interest of the association azacitidine-lenalidomide as frontline therapy in high-risk myelodysplasia or acute myeloid leukemia with complex karyotype.
Scherman E; Malak S; Perot C; Gorin NC; Rubio MT; Isnard F
Leukemia; 2012 Apr; 26(4):822-4. PubMed ID: 21997572
[No Abstract] [Full Text] [Related]
17. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study.
Giagounidis A; Mufti GJ; Mittelman M; Sanz G; Platzbecker U; Muus P; Selleslag D; Beyne-Rauzy O; te Boekhorst P; del Cañizo C; Guerci-Bresler A; Nilsson L; Lübbert M; Quesnel B; Ganser A; Bowen D; Schlegelberger B; Göhring G; Fu T; Benettaib B; Hellström-Lindberg E; Fenaux P
Eur J Haematol; 2014 Nov; 93(5):429-38. PubMed ID: 24813620
[TBL] [Abstract][Full Text] [Related]
18. Reduction of Extramedullary Complications in Patients With Acute Myeloid Leukemia/Myelodysplastic Syndrome Treated With Azacitidine.
Shabanova I; Cada M; Johnston DL; Abbott LS; Leung EW; Schechter T; Dror Y; Klaassen RJ
J Pediatr Hematol Oncol; 2020 Apr; 42(3):170-174. PubMed ID: 32134844
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the
Ades L; Prebet T; Stamatoullas A; Recher C; Guieze R; Raffoux E; Bouabdallah K; Hunault M; Wattel E; Stalnikiewicz L; Toma A; Dombret H; Vey N; Sebert M; Gardin C; Chaffaut C; Chevret S; Fenaux P
Haematologica; 2017 Apr; 102(4):728-735. PubMed ID: 28034993
[TBL] [Abstract][Full Text] [Related]
20. New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide.
Loiseau C; Ali A; Itzykson R
Exp Hematol; 2015 Aug; 43(8):661-72. PubMed ID: 26123365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
